# Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06771622/  
OnCo record `nct06771622` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Trastuzumab, Pertuzumab, Oxaliplatin, Capecitabine, Ramucirumab and Bevacizumab in advanced solid tumours, run by FBD Biologics Limited, active and no longer recruiting.

## Summary

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06771622 by FBD Biologics Limited, with 500 participants enrolled, started 2025-03-13 and due to reach its primary completion in 2028-01-01. Interventions recorded: HCB101, Trastuzumab, Pertuzumab, Oxaliplatin, Capecitabine and Ramucirumab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06771622
- Phase: 1/2
- Setting: Phase Ib/IIa, Open-label, Multicenter, Dose Escalation, and Dose Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of HCB101 in Combination With Multiple Agents in Subjects With Advanced Solid Tumors
- Sponsor: FBD Biologics Limited
- Enrolled: 500

## Sources

- ClinicalTrials.gov NCT06771622: https://clinicaltrials.gov/study/NCT06771622

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Capecitabine](https://onco.cc/drugs/capecitabine/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/), [Pertuzumab](https://onco.cc/drugs/pertuzumab/), [Ramucirumab](https://onco.cc/drugs/ramucirumab/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/)

---
JSON: https://onco.cc/api/v1/entities/nct06771622.json